Two drugs are better than one. A short history of combined therapy of ovarian cancer
- PMID: 26793017
- PMCID: PMC4709392
- DOI: 10.5114/wo.2014.43975
Two drugs are better than one. A short history of combined therapy of ovarian cancer
Abstract
Combined therapy of ovarian cancer has a long history. It has been applied for many years. The first drug which was commonly combined with other chemotherapeutics was cisplatin. It turned out to be effective given together with alkylating agents as well as with taxanes. Another drug which is often the basis of first-line therapy is doxorubicin. The use of traditional chemotherapy is often limited due to side effects. This is why new drugs, targeted specifically at cancer cells (e.g. monoclonal antibodies or epidermal growth factor receptor inhibitors), offer a welcome addition when used in combination with conventional anticancer agents. Drugs applied in combination should be synergistic or at least additive. To evaluate the type of interaction between drugs in a plausible sequence, isobolographic analysis is used. This method allows one to assess whether the two agents could make an efficient combination, which might improve the therapy of ovarian cancer.
Keywords: combined therapy; isobolographic analysis; ovarian cancer; synergism.
Figures
Similar articles
-
Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.Anticancer Drugs. 1998 Jun;9(5):457-63. doi: 10.1097/00001813-199806000-00013. Anticancer Drugs. 1998. PMID: 9660544
-
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.Oncogene. 1999 Apr 1;18(13):2241-51. doi: 10.1038/sj.onc.1202526. Oncogene. 1999. PMID: 10327070
-
New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.Anticancer Drugs. 2005 Feb;16(2):211-21. doi: 10.1097/00001813-200502000-00014. Anticancer Drugs. 2005. PMID: 15655420
-
Medical therapy of advanced malignant epithelial tumours of the ovary.Forum (Genova). 2000 Oct-Dec;10(4):323-32. Forum (Genova). 2000. PMID: 11535983 Review.
-
New potential chemotherapy for ovarian cancer - Combined therapy with WP 631 and epothilone B.Life Sci. 2016 Apr 15;151:86-92. doi: 10.1016/j.lfs.2016.02.095. Epub 2016 Mar 2. Life Sci. 2016. PMID: 26944437 Review.
Cited by
-
Treatment of ovarian cancer: From the past to the new era (Review).Oncol Lett. 2025 Jun 3;30(2):384. doi: 10.3892/ol.2025.15130. eCollection 2025 Aug. Oncol Lett. 2025. PMID: 40535104 Free PMC article. Review.
-
Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges.Molecules. 2022 Aug 28;27(17):5537. doi: 10.3390/molecules27175537. Molecules. 2022. PMID: 36080304 Free PMC article. Review.
-
Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma.Cancers (Basel). 2022 Sep 7;14(18):4357. doi: 10.3390/cancers14184357. Cancers (Basel). 2022. PMID: 36139522 Free PMC article.
-
Potential Therapeutic Implications of Caffeic Acid in Cancer Signaling: Past, Present, and Future.Front Pharmacol. 2022 Mar 9;13:845871. doi: 10.3389/fphar.2022.845871. eCollection 2022. Front Pharmacol. 2022. PMID: 35355732 Free PMC article. Review.
-
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.Int J Mol Sci. 2019 Feb 22;20(4):952. doi: 10.3390/ijms20040952. Int J Mol Sci. 2019. PMID: 30813239 Free PMC article. Review.
References
-
- Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621–81. - PubMed
-
- Loewe S. Die quantitativen probleme der pharmakologie. Ergebn Physiol. 1928;27:47–87.
-
- Gessner PK. Isobolografic analysis of interactions: an update on applications and utility. Toxicology. 1995;105:161–79. - PubMed
-
- McGuire WP. Current status of taxane and platinum-based chemotherapy in ovarian cancer. J Clin Oncol. 2003;21:133–5. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials